Clearmind Medicine (NASDAQ:CMND) Shares Down 1.6% – Should You Sell?

Clearmind Medicine Inc. (NASDAQ:CMND)’s share price fell 1.6% during mid-day trading on Friday . The stock traded as low as $0.52 and last traded at $0.52. 262,552 shares traded hands during trading, a decline of 98% from the average session volume of 12,822,764 shares. The stock had previously closed at $0.5286.

Clearmind Medicine Trading Down 1.6%

The firm has a market capitalization of $780,000.00, a price-to-earnings ratio of -0.03 and a beta of 0.87. The company has a fifty day moving average price of $0.84 and a 200-day moving average price of $4.91.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($3.32) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC grew its position in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 224,378 shares of the company’s stock after buying an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned approximately 4.10% of Clearmind Medicine worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 96.05% of the company’s stock.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.